Aerie Pharmaceuticals Inc. (NASDAQ:AERI) went down by -2.03% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Drug Manufacturers – Specialty & Generic giant went up by $14.46 to trade ended Wednesday trading at $14.76. This is down from the $14.76 price recorded on Tuesday’s trading session. Thanks to this latest performance, AERI is closer to the higher price 52-week target of $50.00 and further from the lowest price target of $16.00. Its performance from the start of the year has also been negative, with AERI down by -40.17% year-to-date.
Aerie Pharmaceuticals Inc. (AERI) started the day trading at $14.77 and recorded an intraday high of $14.9. It also recorded an intraday low of $14.215 during Wednesday’s trading session. Aerie Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -25.59% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 748310, which is less than -25.59 of the total average daily trading volume of 939.80K.
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) 2020 Performance Impressive
The increase in AERI’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of AERI currently stands at $30.65, which is higher than the current trading price of the stock by 52.82%. However, AERI’s current trading price is -33.89% lower than the 52-week low price of $10.80. In terms of trading volume, Aerie Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 748310 shares of Aerie Pharmaceuticals Inc. were traded on the stock exchange on Wednesday, which is less than -25.59% of the 939.80K average trading volume of the stock.
The performance of the stock has been positive over the past year. AERI’s performance over the past one year has seen it plunge by -45.82%, while the stock has gone down by -40.17% in the last six months. The quarterly performance of AERI currently stands at 8.80%, and it is down by -4.49% in the last month. The only negative figure was from the weekly performance, which currently reads -1.43%. At the time of writing AERI’s report, the company has a total market cap of $654.75M, making it one of the largest publicly-traded companies in the world.Aerie Pharmaceuticals Inc. also has over 380 employees all over the world.
AERI Insider Activities
The insider transactions over the past six months are down by -48.20%.For Aerie Pharmaceuticals Inc. insiders bought 108,000 shares in 13 transactions. In that same period, insiders sold 1,032,506 of their shares in 25 transactions. After these transactions, insiders at Aerie Pharmaceuticals Inc. now hold 966.54k shares, which is over 131.45% of the total company stocks. Institutional investors currently hold a large chunk of the AERI shares, as they control 2.08% of the company’s total stock.
AERI Fundamental Analysis
For Aerie Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at -4.41. In the coming year, analysts expect the EPS to be -2.02. The stock’s EPS growth this year is 21.30%, -17.10% in the previous five years. In terms of revenue, Aerie Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.77, which is higher than the average annual revenue of -17.10% over the past half a decade.
The Return on Investment (ROI) on Aerie Pharmaceuticals Inc.’s stock currently stands at -52.70%. The gross margin of the company is 86.70%.
AERI Analysts Prediction
In June 01, 2020, several analysts reiterated their positions on the Aerie Pharmaceuticals Inc. stock and predicted its performance to their investors. The analysts at Oppenheimer believe AERI is still a Outperform and set the price target between $22 and $24. The H.C. Wainwright has a Buy rating for Aerie Pharmaceuticals Inc., predicting the stock price to stay between $37 and $31.
Analysts at H.C. Wainwright believe that AERI is Buy, and they have a price target of between $55 and $41. Citigroup and H.C. Wainwright also believe that Aerie Pharmaceuticals Inc.’s stock is outperforming at the moment. AERI received a positive rating from Needham, which set a price target of $54-$48 for the stock. Three analysts, Cantor Fitzgerald, Piper Jaffray, and Cantor Fitzgerald, all rate the stock as overweight.
At the moment, Aerie Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 1.52, and they have a long-term Debt to Equity ratio of 1.52.
AERI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of AERI currently stands at -3.43%, while the SMA50 is -3.46%. The biggest one is the SMA200, which is currently reading -21.34% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 44.94.